The traditional healthcare delivery model is changing
Payment models and federal reforms are increasingly focused on the real world impact of treatments and devices. Learn how real world evidence is helping to close the evidence gap between traditional clinical trials and the broader patient population.
Get insights on the key contracting issues you should be considering today to optimise the commercial success of your products
As industry shifts from a fee-for-service healthcare delivery model to one with a greater focus on the value a treatment brings to patient health and system outcomes, drug and medical device developers are taking a more integrated approach in developing their product’s regulatory and reimbursement strategies.
ICON is leading the way to support pharma, biotech and medical device clients through its dedicated Commercialisation and Outcomes experts, who apply state-of-the-art technology, advanced methodologies and deep expertise to identify, generate, synthesise and communicate meaningful evidence of their treatments’ value.
Read our whitepaper, The Role of ICER as an Independant HTA Organisation for an depth look at our primary research evaluating ICER’s influence over payers and manufactures, and secondary budget impact analysis on the potential savings to the US healthcare system if ICER’s cost effective prices were implemented in selected therapeutic areas.
Read our white paper, Making Sense of Biosimilars: Strategies and Recommendations to Achieve Optimal Market Access for insights on the key regulatory and development concerns, including recommendations to address biosimilar uptake in the United States and Europe.
Download our white paper, Real World Evidence Generation: The Value of Cross-Sectional Studies and Medical Chart Reviews to learn how this hybrid approach to study design can be advantageous for generating real world evidence. Get insights on the issues you need to consider to ensure that your study is planned to produce robust scientific data that can be extrapolated beyond the study population.
As healthcare systems shift towards value based health care payment models, device developers will need to adopt a strategic approach to maintain premium pricing on the market and to bring new high-value products to market. To be successful, device developers will need an understanding of how incentives are structured and how they influence varying stakeholder interests and behaviours. In addition, they have to identify stakeholder needs early and create strategies for developing evidence to make a compelling value based case for target stakeholder groups.
Read our white paper to learn more about our model for mapping stakeholder value that can help drive profitable device development programmes in increasingly value driven markets.
ICON and ICHOM unveiled the world’s first global patient outcomes benchmarking platform, enabling the collection, storage, aggregation, analysis and visualisation of health outcomes data, at the 2017 ICHOM annual conference.
Through its relationship with ICON, ICHOM is creating a secure central platform where outcomes data is compiled from participating provider organisations around the world. This will enable provider organisations to compare the health outcomes of their patients to those of their peers.
In December 2016, the Centers for Medicare & Medicaid Services (CMS) expanded the Bundled Payments for Care Improvement (BPCI) Initiative to include cardiovascular and hip fracture services, taking a major step in the march towards value-based care in the US.
How can medical device manufacturers sustain growth and successfully navigate this new model? Download our white paper, Thriving in Value-Based Healthcare: A Guide for Cardiovascular Device Manufacturers
Gain insights to best practices for developing a comprehensive health economic and epidemiologic evidence strategy and evidence generation plan that is targeted to meet the needs of regulators and payers.
The demand from regulators and payers for health economic models is increasing, as these key decision makers struggle to manage budget constraints and provide access to new therapies.
The following briefing is drawn from our webinar ‘Using Early Economic Models in Developing Your Evidence Strategy,’ and explains the nature and value of these models and presents guidelines for their development.